Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMP Specific-CTLs in EBV+ Refractory/Recurrent Hodgkin Lymphoma
NCT01636388Phase 2Terminated
- Sponsor
- New York Medical College
- Start
- Jan 2013
- Primary completion
- Jun 2017
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of LMP1/2-specific cytotoxic T-lymphocytes in Hodgkin lymphoma (HL), sponsored by New York Medical College. Started Jan 2013; status: terminated.
02
Drugs
LMP1/2-specific cytotoxic T-lymphocytes
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT01636388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01636388.